Vera Therapeutics (VERA) EBITDA (2020 - 2026)
Vera Therapeutics' (VERA) quarterly EBITDA came in at -$125.1 million in Q1 2026, down 118.79% YoY from $666.1 million in Q1 2025, and down 32.83% on a QoQ basis from -$94.2 million in Q4 2025.
Vera Therapeutics (VERA) EBITDA (2020 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 7 years of EBITDA data on file, last reported at -$125.1 million in Q1 2026.
- Quarterly EBITDA fell 118.79% year-over-year to -$125.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$383.4 million (down 98.4% YoY) and the FY2025 annual result came in at -$315.5 million, down 88.71% from the prior year.
- EBITDA declined to -$125.1 million in Q1 2026, from -$94.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$15.1 million in Q2 2022 to a low of -$125.1 million in Q1 2026.
- A 5-year average of -$47.1 million and a median of -$33.6 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA tumbled 260.92% — and 2023, when it increased 19.51%.
- Tracing VERA's EBITDA over 5 years: stood at -$33.6 million in 2022, then increased by 19.51% to -$27.0 million in 2023, then sank by 80.98% to -$48.9 million in 2024, then plunged by 92.6% to -$94.2 million in 2025, then tumbled by 32.83% to -$125.1 million in 2026.
- The last three EBITDA figures came in at -$125.1 million (Q1 2026), -$94.2 million (Q4 2025), and -$83.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | -112.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -112.49 Mn |
| Mar 31, 2026 | -125.13 Mn |
| Dec 31, 2025 | -94.21 Mn |
| Sep 30, 2025 | -83.93 Mn |
| Jun 30, 2025 | -80.14 Mn |
| Mar 31, 2025 | -57.19 Mn |
| Dec 31, 2024 | -48.91 Mn |
| Sep 30, 2024 | -49.80 Mn |
| Jun 30, 2024 | -37.34 Mn |
| Mar 31, 2024 | -31.11 Mn |
| Dec 31, 2023 | -27.03 Mn |
| Sep 30, 2023 | -21.76 Mn |
| Jun 30, 2023 | -21.97 Mn |
| Mar 31, 2023 | -31.26 Mn |
| Dec 31, 2022 | -33.58 Mn |
| Sep 30, 2022 | -25.24 Mn |
| Jun 30, 2022 | -15.06 Mn |
| Mar 31, 2022 | -17.02 Mn |
| Dec 31, 2021 | -16.59 Mn |
| Sep 30, 2021 | -7.25 Mn |